glp-1 and breast cancer risk Have questions about GLP-1s affect on risk? 🩺 Join Dr. Elizabeth McDonald to learn what her recent study found, why observational research matters, what patients should know today. 📅 GLP-1s in Breast Cancer: Overall

This is largely due to the presence of l-glutathione, a compound known to inhibit melanin production which causes darkening of the skin

This study tested one potent GLP-1 receptor agonist against another that is less potent but still showed an overall reduction in events, she says

The active compound is tirzepatide, a synthetic peptide that acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R)

Summary Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the year